{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["sacituzumab tirumotecan"]],"indication":"previously treated advanced nonsquamous NSCLC with genomic alterations","name":"NCT06074588","nct_id":"NCT06074588","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06074588. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will receive 4 mg/kg of sacituzumab tirumotecan via intravenous (IV) infusion on Days 1, 15 and 29 of each 6-week cycle. Additionally, participants receive diphenhydramine (or equivalent), an H2 antagonist of investigator's choice, acetaminophen (or equivalent), and dexamethasone (or equivalent) per each drug's product label prior to the first 4 infusions of sacituzumab tirumotecan. At subsequent infusions, the H2 antagonist and dexamethasone are optional, at the discretion of the investigator.","label":"Sacituzumab tirumotecan","type":"EXPERIMENTAL"},{"description":"Participants will receive 75 mg/m\\^2 of docetaxel or 500 mg/m\\^2 of pemetrexed by IV infusion on Days 1 and 22 of every 6-week cycle.","label":"Chemotherapy","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2030-03-11","type":"ESTIMATED"},"conditions":["Non-small Cell Lung Cancer (NSCLC)"],"enrollment":{"count":556,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Sacituzumab tirumotecan","otherNames":["SKB264, MK-2870"],"type":"BIOLOGICAL"},{"name":"Docetaxel","otherNames":["TAXOTERE®"],"type":"DRUG"},{"name":"Pemetrexed","otherNames":["ALIMTA®"],"type":"DRUG"}],"last_update":"2026-08-14","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-05-10","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall Survival (OS) of Participants with NSCLC with Epidermal Growth Factor Receptor (EGFR) Mutations","timeFrame":"Up to approximately 41 months"}],"references":[],"start_date":{"date":"2023-11-12","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)","url":"https://clinicaltrials.gov/study/NCT06074588"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06074588"}